Latest filing published 11 Jun 2024 for Deciphera Pharmaceuticals, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Daniel C. Martin in Deciphera Pharmaceuticals, Inc., where the filings describe the role as senior executive. Between 18 September 2018 and 11 June 2024, the trades on record add up to 23 filings.
Every open-market trade on record is a sale: 12 sales worth €2.1M. Outside the open market, there are 8 share grants and 1 option exercise. So far in 2024, the count stands at no purchases and 2 sales.
The newest entry dates from 11 June 2024: a transaction, in Deciphera Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations